SAR 421869

Drug Profile

SAR 421869

Alternative Names: MY07A gene therapy - Oxford Biomedica; Myosin VIIA gene therapy; SAR-421869; Usher syndrome gene therapy - Oxford BioMedica/Sanofi; UshStat

Latest Information Update: 26 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford BioMedica
  • Developer Sanofi
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Usher syndromes
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Usher syndromes

Most Recent Events

  • 26 Oct 2018 Phase-I/II development for Usher syndromes is ongoing in USA and France (NCT01505062) (Oxford BioMedica pipeline, October 2018)
  • 14 Feb 2014 Oxford BioMedica intiates enrolment by invitation only in a follow up phase I trial to assess the long term safety of MY07A gene therapy (NCT02065011)
  • 17 Oct 2013 Oxford BioMedica reaches an agreement with the US FDA to resume recruitment into the phase I/IIa trial for Usher syndromes in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top